Allianz Asset Management GmbH Sells 69,654 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Allianz Asset Management GmbH trimmed its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 10.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 574,422 shares of the company’s stock after selling 69,654 shares during the quarter. Allianz Asset Management GmbH owned about 0.05% of Teva Pharmaceutical Industries worth $11,603,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Phoenix Financial Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 9.4% during the third quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after buying an additional 3,533,800 shares during the last quarter. Menora Mivtachim Holdings LTD. lifted its position in Teva Pharmaceutical Industries by 31.9% in the 2nd quarter. Menora Mivtachim Holdings LTD. now owns 38,493,294 shares of the company’s stock valued at $645,148,000 after acquiring an additional 9,303,978 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. lifted its position in Teva Pharmaceutical Industries by 12.9% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after acquiring an additional 4,306,363 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its stake in Teva Pharmaceutical Industries by 13.6% during the 3rd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 32,582,212 shares of the company’s stock valued at $658,161,000 after purchasing an additional 3,896,790 shares during the last quarter. Finally, Lingotto Investment Management LLP increased its holdings in shares of Teva Pharmaceutical Industries by 1.1% in the 2nd quarter. Lingotto Investment Management LLP now owns 28,156,918 shares of the company’s stock worth $471,910,000 after purchasing an additional 302,975 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE:TEVA opened at $34.69 on Monday. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The stock has a market capitalization of $39.79 billion, a PE ratio of 28.91, a price-to-earnings-growth ratio of 1.98 and a beta of 0.70. The firm’s 50 day moving average price is $31.43 and its 200-day moving average price is $23.92. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. During the same period in the previous year, the business posted $0.71 earnings per share. The firm’s quarterly revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Equities research analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

Insider Buying and Selling

In related news, CAO Amir Weiss sold 12,300 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the transaction, the chief accounting officer directly owned 5,650 shares in the company, valued at approximately $170,630. The trade was a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Sabag sold 216,892 shares of the company’s stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.73, for a total value of $6,231,307.16. Following the completion of the sale, the insider owned 52,828 shares of the company’s stock, valued at approximately $1,517,748.44. The trade was a 80.41% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 422,060 shares of company stock valued at $12,254,965 in the last 90 days. 0.55% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on TEVA. Jefferies Financial Group upped their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. The Goldman Sachs Group lifted their price target on shares of Teva Pharmaceutical Industries from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Barclays boosted their price objective on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a report on Friday, January 30th. Finally, JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a report on Tuesday, December 16th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $36.00.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.